ACE2 and COVID-19: These VOCs can enhance the interactions with the host receptor ACE2, increase viral transmissibility or reduce the potency of neutralizing antibodies, thereby compromising the immune responses in recovered COVID-19 patients or efficacy in vaccinated individuals; these features have resulted in increasing breakthrough infections by VOCs both in both recovered COVID-19 patients and vaccinated individuals.